Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
2055042-69-6
2100306-50-9 | N-(Azido-PEG3)-N-Fluorescein-PEG3-acid | AA019E9E | MFCD30723236
2170240-91-0 | Azido-PEG3-aminoacetic acid-NHS ester | AA019EEI | MFCD31580156
2055646-26-7 | TCO-PEG24-NHS ester | AA019EH9 | MFCD31615442
494795-78-7 | 1-(2-(Piperidin-4-yl)phenyl)ethan-1-ol hydrochloride | AA019EL1 | MFCD30099244
155342-90-8 | N-cyclobutylaniline | AA019ENR | MFCD16107859
147632-26-6 | Methyl 2-methyl-2-(thiophen-3-yl)propanoate | AA019ER4 | MFCD28363367
1187189-41-8 | Ethyl 6-(4-bromo-3-formylphenoxy)-2-ethoxynicotinate | AA019EU1 | MFCD30185084
66225-78-3 | 2-((4R)-4-((3R,5R,6S,7R,10R,13R)-3,6,7-Trihydroxy-10,13-Dimethylhexadecahydro-1H-Cyclopenta[A]Phenanthren-17-Yl)Pentanamido)Acetic Acid | AA019EXC | MFCD31579960
79517-01-4 | Octreotide Acetate | AA019FPN | MFCD00871400
937171-63-6 | (2R,3S)-3-{[(benzyloxy)(hydroxy)phosphoryl]oxy}-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}butanoic acid | AA019FY6 | MFCD07363481
